Breaking News
Home / Business News (page 5)

Business News

QIAGEN and DiaSorin collaborate on novel QuantiFERON-Based Test for Earlier Detection of Lyme Disease

Germantown, Maryland; Hilden, Germany and Saluggia, Italy, June 5, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant unmet medical need. The …

Read More »

UC Berkeley Extension and Innovative Genomics Institute Launch CRISPR Genome Editing Courses

BERKELEY, Calif.–(BUSINESS WIRE)–UC Berkeley Extension and the Innovative Genomics Institute (IGI) announce the launch of a practical training on CRISPR and genome editing. CRISPR is infiltrating nearly every crevice of biology, leading to new discoveries and surprising applications. The fast pace of this technology captures news headlines daily, leaving the public to wonder …

Read More »

Bayer and Arvinas to Collaborate on Proteolysis-Targeting Chimera Candidates for Humans and Plants

NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) — Bayer and Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, today announced an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, …

Read More »

Starpharma Signs Second Oncology Agreement With AstraZeneca

MELBOURNE, Australia–(BUSINESS WIRE)–Starpharma (ASX: SPL, OTCQX: SPHRY) today announced a Development and Option Agreement with AstraZeneca (LON: AZN) to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine. This is the second DEP® commercial agreement Starpharma has signed with AstraZeneca, the first …

Read More »

HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences

CHENGDU, China–(BUSINESS WIRE)–HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover …

Read More »

Biocartis and Kite Sign Agreement for Development of Assays Supporting Kite’s Therapies

Mechelen, Belgium, 1 June 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company (a pharmaceutical company engaged in the development of innovative cancer cell therapies). The …

Read More »

Kite and Humanigen Collaborate to Evaluate Investigational Combination of Yescarta with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SANTA MONICA, Calif. & BURLINGAME, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). …

Read More »

Roche and GE Launch NAVIFY Tumor Board with Medical Imaging Capabilities to Enable More Personalized Decisions in Cancer Care

Basel, 31 May 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the release of NAVIFY Tumor Board 2.0, the first collaboration product from our partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other patient data, the product enables tumour boards – multi-disciplinary teams who …

Read More »

Lantheus Collaborates with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies

NORTH BILLERICA, Mass.–(BUSINESS WIRE)–Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that it has entered into a strategic collaboration and license agreement with NanoMab Technology Limited (“NanoMab”), …

Read More »

Organovo Collaborates with MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney Disease

SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, today announced a collaboration with Professor Melissa Little at the Murdoch Children’s Research Institute (“MCRI”), The Royal Children’s Hospital, …

Read More »